LABETALOL STRAGEN 5 mg/ml, solution for injection/for infusion 5 ampoules of 20 ml
Active ingredients: Labetalol hydrochloride
Commercialized according to BDPMDispensing in France: Prescription only, hospital use
Solution for injection or infusion5 ampoules of 20 mlintraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- LABETALOL STRAGEN 5 mg/mL, solution injectable/pour perfusion
- Pharmaceutical form
- solution injectable ou pour perfusion
- Route of administration
- intraveineuse
- Presentation description
- 5 ampoules en verre de 20 mL
- Marketing authorisation holder
- S.A.L.F. - S.P.A. LABORATORIO FARMACOLOGICO (ITALIE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 19 Nov 2024
- Prescription and dispensing conditions
- Prescription only, hospital use
- List I: prescription-only medicine
- Hospital use only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
61308023CIP75509750CIP133400955097501Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CHLORHYDRATE DE LABÉTALOLsolution | 5 mg · 1 mL de solution | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.